Product image of Memantina Tarbis (Memantine Hydrochloride) supplied by GNH India

Memantina Tarbis

Active Ingredient:
Memantine Hydrochloride
Origin:
EU

Memantina Tarbis (Memantine Hydrochloride)

Memantine, the active ingredient in Memantina Tarbis, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is prescribed to treat moderate to severe Alzheimer’s disease in adult patients. The formulation is designed for systemic absorption and is marketed within the European Union.

GNH India supplies Memantina Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice (GDP) standards, ensuring product quality, traceability, and regulatory compliance across global supply chains.

Manufacturer / TM Owner

Tarbis Farma, S.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Memantine acts on the glutamatergic pathway and is indicated for the following Alzheimer’s disease conditions.
  • Alzheimer’s disease (moderate to severe): improves cognitive function and daily living activities.
  • Alzheimer’s disease (any stage): may help maintain cognition and slow functional decline.
  • Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression.

How It Works

  • Memantine binds to the phencyclidine site of the N‑methyl‑D‑aspartate (NMDA) receptor as a non‑competitive antagonist. By reducing excessive calcium influx through the receptor channel, it limits excitotoxic neuronal injury caused by prolonged glutamate activation. This modulation of excitatory neurotransmission helps preserve neuronal integrity and function in brain regions affected by Alzheimer’s pathology. The drug’s effect is activity‑dependent, preferentially targeting pathologically over‑activated receptors while sparing normal synaptic transmission.

Side Effects

Memantine may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Dizziness
  • Headache
  • Constipation
  • Fatigue

Serious or Rare Side Effects

  • Seizures
  • Severe rash (e.g., Stevens‑Johnson syndrome)
  • Psychosis or suicidal thoughts

Precautions & Warnings

  • When prescribing memantine, clinicians should consider several precautionary measures to ensure safe use.
  • Renal impairment: assess kidney function and adjust dose if necessary.
  • Hepatic impairment: monitor liver enzymes and use with caution.
  • History of seizures: evaluate risk and monitor for seizure activity.
  • Elderly patients: observe for increased sensitivity to dizziness and confusion.
  • Concomitant NMDA antagonists: avoid combined use to prevent additive neurotoxicity.
  • Pregnancy: safety not established; use only if potential benefit justifies potential risk.
  • Store at ambient temperature: keep in original packaging, protect from moisture.

Avoid Interactions

Memantine can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

  • Amantadine: combined NMDA antagonism may increase neurotoxic effects.
  • Ketamine: additive NMDA blockade can enhance central nervous system depression.
  • Other NMDA antagonists: concurrent use may lead to excessive inhibition of glutamatergic signaling.

Moderate Interactions (Monitor Closely)

  • Anticholinergic agents: may worsen cognitive impairment.
  • Diuretics: can potentiate hypotensive effects.
  • CNS depressants (e.g., benzodiazepines): may increase dizziness and sedation.

Frequently Asked Questions

Memantina Tarbis contains memantine, which is prescribed for the treatment of moderate to severe Alzheimer’s disease. It helps improve cognition, memory, and daily functioning in patients with this neurodegenerative condition.

Memantine acts as a non‑competitive antagonist at the NMDA receptor, reducing excessive calcium influx caused by over‑activation of glutamate pathways. This limits excitotoxic neuronal damage and supports neuronal survival in brain areas affected by Alzheimer’s disease.

The dosing regimen for Memantina Tarbis is determined by the prescribing clinician based on the patient’s clinical status, renal function, and response to therapy. Specific dose information should be obtained from the treating healthcare professional.

Safety data for memantine in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Memantine belongs to the NMDA‑receptor antagonist class, whereas other approved agents such as cholinesterase inhibitors (donepezil, rivastigmine) target acetylcholine metabolism. Memantine is typically used in moderate to severe disease and may be combined with a cholinesterase inhibitor for additive benefit.

Store the tablets at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid exposing it to extreme temperatures.

Memantina Tarbis is taken orally, usually with water. The tablet should be swallowed whole and not crushed or chewed, unless otherwise directed by a healthcare professional.

Serious adverse events, although rare, include seizures, severe skin reactions such as Stevens‑Johnson syndrome, and emergence of psychotic symptoms or suicidal thoughts. Patients should be monitored closely for any of these signs and seek immediate medical attention if they occur.

Memantina Tarbis should be avoided in patients with known hypersensitivity to memantine or any excipients, and in individuals taking other NMDA antagonists concurrently. Caution is also advised for patients with uncontrolled seizures, severe renal or hepatic impairment, and pregnant or nursing women unless clearly indicated.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Memantine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT